JP2012526121A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526121A5 JP2012526121A5 JP2012509873A JP2012509873A JP2012526121A5 JP 2012526121 A5 JP2012526121 A5 JP 2012526121A5 JP 2012509873 A JP2012509873 A JP 2012509873A JP 2012509873 A JP2012509873 A JP 2012509873A JP 2012526121 A5 JP2012526121 A5 JP 2012526121A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- formulation
- acid sequence
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17538009P | 2009-05-04 | 2009-05-04 | |
| US61/175,380 | 2009-05-04 | ||
| PCT/US2010/033387 WO2010129469A1 (en) | 2009-05-04 | 2010-05-03 | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012526121A JP2012526121A (ja) | 2012-10-25 |
| JP2012526121A5 true JP2012526121A5 (enExample) | 2013-06-20 |
Family
ID=43030509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012509873A Pending JP2012526121A (ja) | 2009-05-04 | 2010-05-03 | ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20100278822A1 (enExample) |
| EP (1) | EP2427211A4 (enExample) |
| JP (1) | JP2012526121A (enExample) |
| KR (1) | KR20120038406A (enExample) |
| CN (2) | CN104490767A (enExample) |
| AR (1) | AR076748A1 (enExample) |
| AU (1) | AU2010246168A1 (enExample) |
| CA (1) | CA2760185A1 (enExample) |
| IL (1) | IL215643A0 (enExample) |
| MX (1) | MX2011011772A (enExample) |
| NZ (2) | NZ595694A (enExample) |
| RU (1) | RU2560701C2 (enExample) |
| SG (2) | SG10201401995UA (enExample) |
| TW (2) | TW201526923A (enExample) |
| UY (1) | UY32609A (enExample) |
| WO (1) | WO2010129469A1 (enExample) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| HU230048B1 (hu) | 1996-02-09 | 2015-06-29 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazása |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| PL218992B1 (pl) * | 2002-07-19 | 2015-02-27 | Abbott Biotech Ltd | Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| TWI439284B (zh) | 2004-04-09 | 2014-06-01 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| WO2006041970A2 (en) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| KR101465456B1 (ko) | 2005-05-16 | 2014-11-27 | 애브비 바이오테크놀로지 리미티드 | 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도 |
| PT1948235E (pt) | 2005-11-01 | 2013-11-26 | Abbvie Biotechnology Ltd | Métodos de determinação da eficácia de adalimumab em sujeitos com espondilite anquilosante, utilizando ctx-ii e mmp3 como biomarcadores |
| EP2738179A1 (en) | 2006-04-05 | 2014-06-04 | AbbVie Biotechnology Ltd | Antibody purification |
| EP2012586A4 (en) | 2006-04-10 | 2010-08-18 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS |
| WO2007120656A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
| US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
| US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| TWI498137B (zh) | 2006-06-30 | 2015-09-01 | Abbvie Biotechnology Ltd | 自動注射裝置 |
| NZ613356A (en) | 2006-10-27 | 2015-02-27 | Abbvie Biotechnology Ltd | Crystalline anti-htnfalpha antibodies |
| NZ598881A (en) * | 2007-03-29 | 2013-11-29 | Abbvie Inc | Crystalline anti-human il-12 antibodies |
| US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
| CA2693771A1 (en) * | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor |
| WO2009020654A1 (en) | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| KR20210049186A (ko) * | 2007-11-30 | 2021-05-04 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| CA2710333A1 (en) * | 2008-01-03 | 2009-07-09 | Abbott Biotechnology Ltd. | Predicting long-term efficacy of a compound in the treatment of psoriasis |
| EP2249809A1 (en) | 2008-01-15 | 2010-11-17 | Abbott GmbH & Co. KG | Powdered protein compositions and methods of making same |
| MX2011011541A (es) | 2009-04-29 | 2012-02-28 | Abbott Biotech Ltd | Dispositivo de inyeccion automatico. |
| US8758301B2 (en) | 2009-12-15 | 2014-06-24 | Abbvie Biotechnology Ltd | Firing button for automatic injection device |
| WO2011097301A2 (en) | 2010-02-02 | 2011-08-11 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR |
| CA2801917C (en) | 2010-06-03 | 2017-04-25 | Abbvie Biotechnology Ltd | Uses and compositions for treatment of hidradenitis suppurativa (hs) |
| CN106267189B (zh) | 2010-10-06 | 2021-02-26 | 瑞泽恩制药公司 | 含有抗白介素-4受体(il-4r)的抗体的稳定制剂 |
| CN103458926B (zh) | 2010-11-11 | 2016-10-26 | 艾伯维生物技术有限公司 | 改进的高浓度抗TNF α 抗体液体制剂 |
| RU2602039C2 (ru) | 2011-01-24 | 2016-11-10 | Эббви Байотекнолоджи Лтд. | Автоматические инъекционные устройства, имеющие наформованные поверхности захвата |
| JP5458188B2 (ja) * | 2011-02-17 | 2014-04-02 | 協和発酵キリン株式会社 | 抗ｃｄ４０抗体の高濃度製剤 |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| TWI907924B (zh) * | 2011-05-02 | 2025-12-11 | 日商武田藥品工業股份有限公司 | 抗-α4β7抗體之調配物 |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| WO2013096835A1 (en) * | 2011-12-23 | 2013-06-27 | Abbvie Inc. | Stable protein formulations |
| US10093728B2 (en) | 2012-03-07 | 2018-10-09 | Cadila Healthcare Limited | Pharmaceutical formulations of TNF-alpha antibodies |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| US20150150982A1 (en) * | 2012-06-12 | 2015-06-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| KR20150043523A (ko) | 2012-09-02 | 2015-04-22 | 애브비 인코포레이티드 | 단백질 불균일성의 제어 방법 |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| MX2015003007A (es) | 2012-09-07 | 2015-06-05 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab. |
| EP2919801B1 (en) * | 2012-10-26 | 2020-04-29 | Lupin Atlantis Holdings, SA | Stable pharmaceutical composition of the tnfr:fc fusion protein etanercept |
| US9649383B2 (en) * | 2012-11-19 | 2017-05-16 | Merck Sharp & Dohme Corp. | Liquid formulations for TNFR:Fc fusion proteins |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| EP2934587A4 (en) * | 2012-12-18 | 2016-08-03 | Merck Sharp & Dohme | Liquid formulations for an anti-TNF-alpha-antibody |
| CN102988984B (zh) * | 2012-12-21 | 2015-05-20 | 嘉和生物药业有限公司 | 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂 |
| CN105051064A (zh) * | 2013-01-24 | 2015-11-11 | 葛兰素史克知识产权开发有限公司 | 抗TNF-α抗原结合蛋白 |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| JP2016515515A (ja) | 2013-03-15 | 2016-05-30 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | 抗プロラクチン受容体抗体製剤 |
| CN103446583B (zh) * | 2013-03-21 | 2015-11-18 | 百奥泰生物科技(广州)有限公司 | 一种治疗TNF-α相关疾病的人抗体制剂 |
| JP2014202667A (ja) * | 2013-04-08 | 2014-10-27 | 株式会社島津製作所 | 抗体医薬用粒子径分布測定装置及び抗体医薬の粒子径分布測定方法 |
| EP3003369A4 (en) * | 2013-05-28 | 2017-04-26 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions comprising pyrophosphate |
| EP3021833B2 (en) * | 2013-07-19 | 2022-03-30 | Hexal Aktiengesellschaft | Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| JP6526025B2 (ja) * | 2013-10-16 | 2019-06-05 | オンコバイオロジクス，インコーポレイティド | 抗体安定性を増強する緩衝液製剤 |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| CN113350278B (zh) | 2013-10-24 | 2023-03-24 | 阿斯利康(瑞典)有限公司 | 稳定的水性抗体配制品 |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| CN104666242B (zh) * | 2013-11-26 | 2018-01-02 | 信达生物制药(苏州)有限公司 | 一种稳定的抗TNF‑α抗体制剂及其用途 |
| BR112016011224A2 (pt) * | 2013-11-29 | 2017-09-19 | Ares Trading Sa | Formulação líquida de uma proteína de fusão que compreende tnfr e região de fc |
| CN104707146B (zh) * | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
| EP3125923B1 (en) * | 2014-03-29 | 2024-10-16 | Intas Pharmaceuticals Limited | Lyophilized pharmaceutical composition of fc-peptide fusion protein |
| EP2946767B1 (en) * | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| PL2946765T3 (pl) * | 2014-05-23 | 2017-08-31 | Ares Trading S.A. | Ciekła kompozycja farmaceutyczna |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| DK3149045T3 (da) * | 2014-05-27 | 2023-03-06 | Academia Sinica | Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt |
| KR20170018810A (ko) * | 2014-06-10 | 2017-02-20 | 메이지 세이카 파루마 가부시키가이샤 | 안정한 아달리무맙 수성 제제 |
| TW201628649A (zh) * | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
| US10696735B2 (en) | 2015-01-21 | 2020-06-30 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| AR103544A1 (es) * | 2015-01-28 | 2017-05-17 | Mabxience S A | FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a |
| EP3053572A1 (en) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| CN108699557B (zh) | 2015-12-04 | 2025-08-15 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| CN109563161A (zh) * | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
| WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
| PH12018502670B1 (en) * | 2016-06-30 | 2023-03-24 | Celltrion Inc | Stable liquid pharmaceutical preparation |
| KR20230041834A (ko) | 2016-08-16 | 2023-03-24 | 리제너론 파아마슈티컬스, 인크. | 혼합물로부터 개별 항체들을 정량하는 방법 |
| CN119492842A (zh) | 2016-10-25 | 2025-02-21 | 里珍纳龙药品有限公司 | 用于色谱数据分析的方法和系统 |
| RU2665966C2 (ru) * | 2016-12-30 | 2018-09-05 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| EP3372242A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372241A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| KR20190130608A (ko) | 2017-03-22 | 2019-11-22 | 노파르티스 아게 | 면역종양학을 위한 조성물 및 방법 |
| CN110352201A (zh) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | 用于癌症疗法的抗体药物缀合物的皮下施用 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| CN107485713B (zh) * | 2017-07-31 | 2018-08-28 | 百奥泰生物科技(广州)有限公司 | 针对TNF-α的抗体组合物及其应用 |
| KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
| CN118416215A (zh) | 2017-09-19 | 2024-08-02 | 里珍纳龙药品有限公司 | 减少粒子形成的方法以及由其形成的组合物 |
| PT3684407T (pt) | 2017-09-20 | 2026-03-30 | Alvotech Hf | Formulações farmacêuticas para adalimumab |
| EA202090802A1 (ru) | 2017-09-30 | 2020-08-05 | Биоселз (Бейдзин) Биотек Ко., Лтд. | Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью |
| EA201900360A1 (ru) * | 2017-12-29 | 2019-12-30 | Закрытое Акционерное Общество "Биокад" | ВОДНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО МОНОКЛОНАЛЬНОГО АНТИТЕЛА К ФНОα |
| TW202003036A (zh) * | 2018-03-23 | 2020-01-16 | 德商艾伯維德國有限及兩合公司 | 穩定水性抗-tau抗體調配物 |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| CN113056482A (zh) | 2018-10-18 | 2021-06-29 | 默沙东公司 | 抗rsv抗体的制剂及其使用方法 |
| CN120842406A (zh) | 2018-10-31 | 2025-10-28 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| EP3934620A1 (en) | 2019-03-05 | 2022-01-12 | Regeneron Pharmaceuticals, Inc. | Human serum albumin in formulations |
| CN113727730A (zh) * | 2019-03-18 | 2021-11-30 | 阿尔沃科技Hf公司 | 高浓度TNFα抗体的含水制剂 |
| EP4153234A1 (en) * | 2020-05-21 | 2023-03-29 | Shilpa Biologicals Private Limited | Pharmaceutical compositions comprising adalimumab |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5237054A (en) * | 1987-02-20 | 1993-08-17 | Akzo Pharma | Stabilized aqueous composition containing antibodies |
| US5945098A (en) * | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| GB9122820D0 (en) * | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| ZA955642B (en) * | 1994-07-07 | 1997-05-06 | Ortho Pharma Corp | Lyophilized imaging agent formulation |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| HU230048B1 (hu) * | 1996-02-09 | 2015-06-29 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazása |
| GB9610992D0 (en) * | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| SE9803710L (sv) * | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Användning av vissa substanser för behandling av nervrotsskador |
| EP1174148A4 (en) * | 1999-04-28 | 2005-05-04 | Yamanouchi Pharma Co Ltd | PARENTAL MEDICAL COMPOSITIONS CONTAINING FRAGMENTS OF HUMANIZED MONOCLONAL ANTIBODIES AND METHOD FOR STABILIZING THE SAME |
| DE10022092A1 (de) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| JP5490972B2 (ja) * | 2000-08-04 | 2014-05-14 | 中外製薬株式会社 | タンパク質注射製剤 |
| UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| SE0003045D0 (sv) * | 2000-08-29 | 2000-08-29 | Probi Ab | New method |
| JP4340062B2 (ja) * | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | 粘度の減少した濃縮タンパク質製剤 |
| BR0206160A (pt) * | 2001-05-25 | 2004-10-26 | Abbott Gmbh & Co Kg | Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos |
| EP1391209A4 (en) * | 2001-05-30 | 2009-12-16 | Chugai Pharmaceutical Co Ltd | PROTEIN PREPARATION |
| AU2002320122B2 (en) * | 2001-06-21 | 2007-07-26 | Genentech, Inc. | Sustained release formulation |
| AU2002324556A1 (en) * | 2001-07-25 | 2003-02-17 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| ES2392073T3 (es) * | 2001-11-08 | 2012-12-04 | Abbott Biotherapeutics Corp. | Formulación farmacéutica líquida estable de anticuerpos IGG |
| US20030143603A1 (en) * | 2001-11-30 | 2003-07-31 | Jill Giles-Komar | Anti-TNF antibodies, compositions, methods and uses |
| GB0202633D0 (en) * | 2002-02-05 | 2002-03-20 | Delta Biotechnology Ltd | Stabilization of protein preparations |
| EP3192528A1 (en) * | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
| US20030161828A1 (en) * | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
| US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| EP1551875A4 (en) * | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF |
| PL218992B1 (pl) * | 2002-07-19 | 2015-02-27 | Abbott Biotech Ltd | Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| AU2004210679A1 (en) * | 2003-02-10 | 2004-08-26 | Elan Pharmaceuticals, Inc. | Immunoglobulin formulation and method of preparation thereof |
| BRPI0407649A (pt) * | 2003-02-28 | 2006-02-21 | Ares Trading Sa | formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação |
| CA2517310C (en) * | 2003-02-28 | 2015-11-24 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations comprising a poloxamer |
| AU2004229335C1 (en) * | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
| FR2853551B1 (fr) * | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee |
| US8496930B2 (en) * | 2003-10-01 | 2013-07-30 | Kyowa Hakko Kirin Co., Ltd | Method of stabilizing antibody and stabilized solution-type antibody preparation |
| DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
| EP1712240B1 (en) * | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
| EP1987843A3 (en) * | 2004-03-12 | 2011-10-26 | Intercell AG | Method for solubilising peptide mixtures |
| US7279448B2 (en) * | 2004-07-08 | 2007-10-09 | The United States Of America, As Represented By The Secretary Of Agriculture | Poly(hydroxy thioether) vegetable oil derivatives useful as lubricant additives |
| TW200621282A (en) * | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| US7119876B2 (en) * | 2004-10-18 | 2006-10-10 | Asml Netherlands B.V. | Lithographic apparatus and device manufacturing method |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| TWI398272B (zh) * | 2005-03-08 | 2013-06-11 | Intervet Int Bv | 化學定義的安定劑 |
| ES2407468T3 (es) * | 2005-04-18 | 2013-06-12 | Yeda Research And Development Company Limited | Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas |
| KR101465456B1 (ko) * | 2005-05-16 | 2014-11-27 | 애브비 바이오테크놀로지 리미티드 | 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도 |
| ATE501248T1 (de) * | 2005-07-02 | 2011-03-15 | Arecor Ltd | Stabile wässrige systeme mit proteinen |
| JP2009502972A (ja) * | 2005-07-29 | 2009-01-29 | アムジエン・インコーポレーテツド | タンパク質凝集を抑制する製剤 |
| WO2007019232A2 (en) * | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| AU2006295340B2 (en) * | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
| US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| PT1948235E (pt) * | 2005-11-01 | 2013-11-26 | Abbvie Biotechnology Ltd | Métodos de determinação da eficácia de adalimumab em sujeitos com espondilite anquilosante, utilizando ctx-ii e mmp3 como biomarcadores |
| JP5405122B2 (ja) * | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| RS52459B (sr) * | 2006-02-07 | 2013-02-28 | Shire Human Genetic Therapies Inc. | Stabilizovane kompozicije glukocerebrozidaze |
| EP2738179A1 (en) * | 2006-04-05 | 2014-06-04 | AbbVie Biotechnology Ltd | Antibody purification |
| WO2007120656A2 (en) * | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
| EP2012586A4 (en) * | 2006-04-10 | 2010-08-18 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS |
| US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| JP2009534390A (ja) * | 2006-04-21 | 2009-09-24 | アムジェン インコーポレイテッド | 生物医薬品製剤のための緩衝剤 |
| US20100021451A1 (en) * | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| TWI498137B (zh) * | 2006-06-30 | 2015-09-01 | Abbvie Biotechnology Ltd | 自動注射裝置 |
| AU2007300221A1 (en) * | 2006-09-25 | 2008-04-03 | Medimmune, Llc. | Stabilized antibody formulations and uses thereof |
| EP2081553B1 (en) * | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
| JP5623743B2 (ja) * | 2006-10-20 | 2014-11-12 | アムジエン・インコーポレーテツド | 安定なポリペプチド製剤 |
| NZ613356A (en) * | 2006-10-27 | 2015-02-27 | Abbvie Biotechnology Ltd | Crystalline anti-htnfalpha antibodies |
| US20080139792A1 (en) * | 2006-12-06 | 2008-06-12 | Wyeth | High Protein Concentration Formulations Containing Mannitol |
| GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| JP5401446B2 (ja) * | 2007-04-26 | 2014-01-29 | バイエル ヘルスケア エルエルシー | 凍結貯蔵を目的とした、組み換えタンパク質溶液の安定化 |
| US8092998B2 (en) * | 2007-05-31 | 2012-01-10 | Abbott Laboratories | Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders |
| EP2150537A4 (en) * | 2007-06-01 | 2010-09-22 | Acologix Inc | STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE |
| WO2008150490A2 (en) * | 2007-06-01 | 2008-12-11 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriasis and crohn's disease |
| WO2009006301A2 (en) * | 2007-06-29 | 2009-01-08 | Battelle Memorial Institute | Protein stabilization |
| CA2693771A1 (en) * | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor |
| US20090029794A1 (en) * | 2007-07-23 | 2009-01-29 | Yung-Hsiung Chen | Golf Club Head that Reduces a Contact Resistance with the Ground |
| WO2009020654A1 (en) * | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| MX2010010503A (es) * | 2008-03-24 | 2010-11-09 | Abbott Biotech Ltd | Metodos y composiciones para tratar perdida osea. |
| MX2011011541A (es) * | 2009-04-29 | 2012-02-28 | Abbott Biotech Ltd | Dispositivo de inyeccion automatico. |
| WO2011097301A2 (en) * | 2010-02-02 | 2011-08-11 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR |
-
2010
- 2010-05-03 NZ NZ595694A patent/NZ595694A/xx not_active IP Right Cessation
- 2010-05-03 CN CN201410669393.5A patent/CN104490767A/zh active Pending
- 2010-05-03 MX MX2011011772A patent/MX2011011772A/es not_active Application Discontinuation
- 2010-05-03 WO PCT/US2010/033387 patent/WO2010129469A1/en not_active Ceased
- 2010-05-03 NZ NZ613809A patent/NZ613809A/en not_active IP Right Cessation
- 2010-05-03 JP JP2012509873A patent/JP2012526121A/ja active Pending
- 2010-05-03 US US12/772,595 patent/US20100278822A1/en not_active Abandoned
- 2010-05-03 SG SG10201401995UA patent/SG10201401995UA/en unknown
- 2010-05-03 CA CA2760185A patent/CA2760185A1/en not_active Abandoned
- 2010-05-03 AU AU2010246168A patent/AU2010246168A1/en not_active Abandoned
- 2010-05-03 KR KR1020117029006A patent/KR20120038406A/ko not_active Withdrawn
- 2010-05-03 RU RU2011149327/15A patent/RU2560701C2/ru not_active IP Right Cessation
- 2010-05-03 EP EP10772644.0A patent/EP2427211A4/en not_active Withdrawn
- 2010-05-03 CN CN201080030083.9A patent/CN102458469B/zh not_active Expired - Fee Related
- 2010-05-03 SG SG2011074341A patent/SG175188A1/en unknown
- 2010-05-04 TW TW104107818A patent/TW201526923A/zh unknown
- 2010-05-04 UY UY0001032609A patent/UY32609A/es not_active Application Discontinuation
- 2010-05-04 AR ARP100101510A patent/AR076748A1/es unknown
- 2010-05-04 TW TW099114238A patent/TWI480064B/zh not_active IP Right Cessation
-
2011
- 2011-10-09 IL IL215643A patent/IL215643A0/en unknown
-
2014
- 2014-01-31 US US14/170,061 patent/US20140141008A1/en not_active Abandoned
- 2014-01-31 US US14/170,026 patent/US20140141007A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534052A5 (enExample) | ||
| RU2011149327A (ru) | Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа | |
| KR102359181B1 (ko) | 항-ｒｓｖ 모노클로날 항체 제제 | |
| JP4764818B2 (ja) | 組換えｉｌ−９抗体およびその使用 | |
| EP2750708B1 (en) | Influenza virus antibody compositions | |
| JP6797767B2 (ja) | バイオ医薬品の投与に関連した免疫応答を調節可能にする方法および製剤 | |
| JP2020518599A5 (enExample) | ||
| US10752676B2 (en) | Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile | |
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| JP2015527402A5 (enExample) | ||
| JP2019504086A5 (enExample) | ||
| JP2016533335A5 (enExample) | ||
| JP2019514998A5 (enExample) | ||
| JP2019536761A5 (enExample) | ||
| HRP20200102T1 (hr) | Formulacije protutijela anti-pdl1 | |
| ES2925232T3 (es) | Proceso para la formulación farmacéutica liofilizada de una proteína terapéutica | |
| TW201444866A (zh) | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 | |
| JP2013543505A5 (enExample) | ||
| HRP20120893T1 (hr) | Formulacija protutijela na histidin-acetatnom puferu | |
| JP2015526440A5 (enExample) | ||
| KR20200131303A (ko) | 염증성 장질환의 치료를 위한 항-il-36r 항체의 용도 | |
| PE20050586A1 (es) | Preparacion farmaceutica que comprende un anticuerpo contra el receptor egfr | |
| JP2011173914A5 (enExample) | ||
| HRP20240635T1 (hr) | Dugodjelujući hormoni rasta i postupci proizvodnje istog | |
| JP2024506940A5 (enExample) |